A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus.
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2012
At a glance
- Drugs Nateglinide (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ENERGY 2
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 01 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record